Program

99
92
5
3
2
1
1

Journal Year Published

3
12
16
11
20
10
8
9
10
12
12
10
12
4

Author

149
201
181
139
133
133
125
123
108
105
95
82
78
63
62
54
50
46
43
43

Category

75
47
31
25
6
5
2
2
2
1
1

Keyword

58
43
32
19
18
16
15
15
14
13
13
12
12
12
11
11
10
10
10
9

Journal

16
13
12
5
4
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2

NCATS Publications

Cytosolic Aspartate Availability Determines Cell Survival When Glutamine Is Limiting.


Alkan HF, Walter KE, Luengo A, Madreiter-Sokolowski CT, Stryeck S, Lau AN, Al-Zoughbi W, Lewis CA, Thomas C, Hoefler G, Graier WF, Madl T, Vander Heiden MG, Bogner-Strauss JG


Cell Metab. , 2018.

Article Pubmed

Sample image from publication page

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.


Moaddel R, Shardell M, Khadeer M, Lovett J, Kadriu B, Ravichandran S, Morris P, Yuan P, Thomas C, Gould TD, Ferrucci L, Zarate CA


Psychopharmacology (Berl.) , (235), 3017-3030, 2018.

Article Pubmed

Sample image from publication page

Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy.


Feliz-Mosquea YR, Christensen AA, Wilson AS, Westwood B, Varagic J, Meléndez GC, Schwartz AL, Chen QR, Mathews Griner L, Guha R, Thomas C, Ferrer-Alegre M, Merino MJ, Cook KL, Roberts DD, Soto-Pantoja DR


Breast Cancer Res. Treat. , (172), 69-82, 2018.

Article Pubmed

miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.


Meyer SE, Muench DE, Rogers AM, Newkold TJ, Orr E, O'Brien E, Perentesis JP, Doench JG, Lal A, Morris P, Thomas C, Lieberman J, McGlinn E, Aronow BJ, Salomonis N, Grimes HL


J. Exp. Med. , (215), 2115-2136, 2018.

Article Pubmed

Sample image from publication page

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.


Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, Mendoza A, Patidar R, Zhang X, Guha R, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen JQ, Walton A, Awasthi P, Edmondson EF, Difilippantonio S, Wei JS, Zhao K, Ferrer-Alegre M, Thomas C, Khan J


Sci Transl Med , (10), 2018.

Article Pubmed

Sample image from publication page

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.


Zanos P, Moaddel R, Morris P, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas C, Zarate CA, Gould TD


Pharmacol. Rev. , (70), 621-660, 2018.

Article Pubmed

Sample image from publication page

Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures.


Dyall J, Nelson EA, DeWald LE, Guha R, Hart BJ, Zhou H, Postnikova E, Logue J, Vargas WM, Gross R, Michelotti J, Deiuliis N, Bennett RS, Crozier I, Holbrook MR, Morris P, Klumpp-Thomas C, McKnight C, Mierzwa T, Shinn P, Glass PJ, Johansen LM, Jahrling PB, Hensley LE, Olinger GG, Thomas C, White JM


J. Infect. Dis. , 2018.

Article Pubmed

Sample image from publication page

A multiprotein supercomplex controlling oncogenic signalling in lymphoma.


Phelan JD, et al.


Nature , 2018.

Article Pubmed

Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells.


Ferrer-Alegre M, Gosline SJC, Stathis M, Zhang X, Guo X, Guha R, Ryman DA, Wallace MR, Kasch-Semenza L, Hao H, Ingersoll R, Mohr D, Thomas C, Verma S, Guinney J, Blakeley JO


Sci Data , (5), 180106, 2018.

Article Pubmed

Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.


McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer-Alegre M, Thomas C, Wei Y, Davani D, Guidos CJ, Khan J, Gladdy RA


Oncogene , 2018.

Article Pubmed